Spinal Muscular Atrophy Foundation

[email protected]
Join the Registry
Learn more about:
Spinal muscular atrophy Spinal muscular atrophy type 2 Spinal muscular atrophy- type 3
Related Access Program
Pfizer – Non Small Cell Lung Cancer With ALK or ROS1 Rearrangement Pfizer – Non Small Cell Lung Cancer Harboring Molecular Alterations Biogen – Infantile-onset Spinal Muscular Atrophy Novartis Pharmaceuticals – Non-small Cell Lung Cancer (NSCLC) Biogen – Infantile-onset Spinal Muscular Atrophy (SMA)

The mission of the SMA Foundation is to accelerate the development of a treatment for SMA, the number one genetic killer of infants and toddlers.

The SMA Foundation was established in 2003 by Loren Eng and Dinakar Singh, parents of a child with SMA. Today, the SMA Foundation is the leading funder of SMA research worldwide–over $110M has been spent on basic, translational, and clinical research. We have invested more than $30M on developing critical, validated research tools and other drug discovery assets. Our mandate is to ensure that all of the results of our research funding are made readily available to every SMA researcher with minimal cost and obligation.

The SMA Foundation operates as a unique blend of non-profit, venture capital, and biotech entities. Our leadership comprises seasoned pharmaceutical, biotech, and finance professionals. Because of our innovative strategy and business model, the SMA Foundation frequently serves as an advisor to government, non-profits, universities, professional societies, and the private sector.

Spinal Muscular Atrophy Foundation 
888 Seventh Avenue  
Suite 400  
New York, NY 10019 
Toll-free: 877-FUND-SMA (877-386-3762)  
Telephone: 646-253-7100  
Fax: 212-247-3079  
E-mail: [email protected] 
Website: http://www.smafoundation.org